Table 1.
Disclosures of the working group members.
| Author | Discipline and affiliation | Intellectual and financial disclosures |
|---|---|---|
| Else Charlotte Sandset | Neurologist, Stroke Unit, Department of Neurology, Oslo University Hospital, Oslo, Norway Senior Researcher,The Norwegian Air Ambulance, Oslo, Norway |
Intellectual disclosures: Trial Manager of the SCAST trial International Advisory Board of the RIGHT2 trial International Advisory Board of the INTERACT4 trial Secretary General of the European Stroke Organisation Financial disclosures: None |
| Craig S. Anderson | Professor of Neurology The George Institute for Global Health, Faculty of Medicine, University of New South Wales, Sydney, NSW, Australia Executive Director The George Institute China at Peking University Health Science Center, Beijing, PR China |
Intellectual disclosures: Principle Investigator for INTERACT, ENCHANTED and TRIDENT studies Financial disclosures: Research grants from Takeda China |
| Philip M. Bath, | Stroke Physician, Stroke Trials Unit, Division Clinical Neuroscience, University of Nottingham, Nottingham NG7 2UH UK | Intellectual disclosures: CI ENOS, RIGHT, RIGHT-2 Member Trial Steering Committees/Advisory Committees: SCAST, INTERACT-1/2, ENCHANTED Financial disclosures: Member advisory Boards - DiaMedica, Moleac, Phagenesis (none relevant to this topic) |
| Hanne Christensen | Professor of Neurology and Consultant Neurologist Department of Neurology, Bispebjerg Hospital & University of Copenhagen, Copenhagen, Denmark. |
Intellectual disclosures: Member Trial Steering Committee ENOS Financial disclosures: Speaker honoraria: Bayer. Daiichi-Sankyo, BMS og Boerhinger. National Coordinating Investigator: Portola and Bayer |
| Urs Fischer | Prof. for Acute Neurology and Stroke; Co-Chairman Stroke Centre Bern Deputy-Director Clinical Trial Unit Bern University of Bern Switzerland |
Intellectual disclosures: Steering Committee Member of the TRIDENT trial Financial disclosures: Consultant for Medtronic, Stryker and CSL Behring (none relevant for this topic) |
| Dariusz Gąsecki | Neurologist, Stroke Unit, Department of Adult Neurology, Medical Univeristy of Gdańsk, Gdańsk, Poland |
Intellectual disclosures: Trial Participant of the SCAST trial Past-President of the European Society of Hypertension Working Group on Hypertension and the Brain Financial disclosures:none |
| Avtar Lal | Guidelines Methodologist, European Stroke Organisation, Basel, Switzerland | Intellectual disclosures: None Financial disclosures: None |
| Lisa S. Manning | Stroke Physician, Department of Stroke Medicine, University Hospitals of Leicester NHS Trust, UK | Intellectual disclosures: None Financial disclosures: None |
| Simona Sacco | Neurologist Department of Biotechnological and Applied Clinical Sciences andBiotechnology, University of L’Aquila, Italy | Intellectual disclosures: Co-chair of the Guideline Board of the European Stroke Organization Financial disclosures: Personal fees as speaker or advisor: Abbott, Allergan, AstraZeneca, Eli Lilly, Novartis, Teva. Research grants: Allergan, Novartis. Non-financial support: Abbott, Allergan, Bayer, Bristol-Myers Squibb, Daiichi-Sankyo, Eli Lilly, Medtronic, Novartis, Pfizer, Starmed, Teva. Fees for CME/education: Medscape |
| Thorsten Steiner | Neurologist, Neurointensivist, Department of Neurology, Frankfurt Hoechst Hospital, Frankfurt, Germany Scientific co-worker, lecturer, Department of Neurology, Heidelberg University Hospital, Heidelberg, Germany |
Intellectual disclosures: ATACH-2, Financial disclosures: Personal fees: Bayer, Boehringer, BMS-Pfizer, Daiichy Sankyo, Alexion |
| Georgios Tsivgoulis | Professor of Neurology,‘Attikon’ University Hospital,Second Department of Neurology,School of Medicine, National and KapodistrianUniversity of Athens,Athens, Greece & Department of Neurology, University of Tennessee Health Science Center, Memphis, Tennessee, USA | Intellectual disclosures: - Section Editor: “Stroke” journal - Associate Editor: “Therapeutics advances in Neurological Disorders” journal -Chair of European Stroke Organization Industry Roundtable Financial disclosures: - Participation in advisory meetings & satellite symposia for Boehringer-Ingelheim; Novartis, Sanofi, Biogen, Genesis Pharma, Teva, Merck-Serono, Bayer, Daichii-Sankyo, Allergan, Specifar, Actavis, Shire, Medtronic, CSL Behring, Abbvie, Abbott, Takeda, Biomarin. - Unrestricted research grants from Novartis, Genesis Pharma, Teva, Shire, Merck-Serono, Medtronic, Boehringer-Ingelheim, Allergan, Abbott |